An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
Nature Cell Biology2014Vol. 16(5), pp. 457–468
Citations Over TimeTop 1% of 2014 papers
Laetitia Seguin, Shumei Kato, Aleksandra Franovic, Maria F. Camargo, Jacqueline Lesperance, Kathryn C. Elliott, Mayra Yebra, Ainhoa Mielgo, Andrew M. Lowy, Hatim Husain, Tina Cascone, Lixia Diao, Jing Wang, Ignacio I. Wistuba, John V. Heymach, Scott M. Lippman, Jay S. Desgrosellier, Sudarshan Anand, Sara M. Weis, David A. Cheresh
Related Papers
- → Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma(2011)45 cited
- → Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Therapy(2014)23 cited
- → [ 11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice(2017)8 cited
- → Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.(2020)3 cited
- In vitro effects of erlotinib and gemcitabine in erlotinib-resistant cells(2006)